Dhaya Seshasayee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dhaya Seshasayee has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Patrick Caplazi
Pathology, Genentech, South San Francisco, California 94080, USA
2 shared publications Yan Wu
Department of Antibody Engineering, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
2 shared publicationsZora Modrusan
Department of Protein Sciences, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
2 shared publicationsAdeyemi O. Adedeji
Department of Developmental Sciences Translational Safety, Genentech, South San Francisco, CA, USA
1 shared publication- Aija Kusi
Department of Developmental Sciences Translational Safety, Genentech, South San Francisco, CA, USA
1 shared publication Akiko Seki
Department of Cancer Immunology, Genentech, 1 DNA Way, South San Francisco, USA
1 shared publication
Latest Publications
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models
T cell–engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (T reg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. T reg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating T reg cells. Monoclonal antibody (mAb)–mediated T reg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing T reg cells in a T cell–mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral T reg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti–PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of T reg cells.
- 28 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (873)
T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models
T cell–engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (T reg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. T reg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating T reg cells. Monoclonal antibody (mAb)–mediated T reg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing T reg cells in a T cell–mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral T reg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti–PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of T reg cells.
- 4 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (605)
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis
TGFβ2 and TGFβ3 isoforms are activated via unique mechanisms and are associated with fibrosis in human diseases.
- 4 August 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (605)
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis
TGFβ2 and TGFβ3 isoforms are activated via unique mechanisms and are associated with fibrosis in human diseases.
- Open Access
- 29 June 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (3) , e0020221
Potent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
Antibiotic treatment of life-threatening P. aeruginosa infections is associated with low clinical success, despite the availability of antibiotics that are active in standard microbiological in vitro assays, affirming the need for new therapeutic approaches. Antibiotics often fail in the preclinical stage due to insufficient efficacy against P. aeruginosa .
- 29 June 2021
- Published by American Society for Microbiology in mBio
- Vol. 12 (3) , e0020221
Open AccessPotent Killing of Pseudomonas aeruginosa by an Antibody-Antibiotic Conjugate
Antibiotic treatment of life-threatening P. aeruginosa infections is associated with low clinical success, despite the availability of antibiotics that are active in standard microbiological in vitro assays, affirming the need for new therapeutic approaches. Antibiotics often fail in the preclinical stage due to insufficient efficacy against P. aeruginosa .
- 22 March 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (4) , 735-746
Immune repertoire mining for rapid affinity optimization of mouse monoclonal antibodies
Traditional hybridoma and B cell cloning antibody discovery platforms have inherent limits in immune repertoire sampling depth. One consequence is that monoclonal antibody (mAb) leads often lack the necessary affinity for therapeutic applications, thus requiring labor-intensive and time-consuming affinity in vitro engineering optimization steps. Here, we show that high-affinity variants of mouse-derived mAbs can be rapidly obtained by testing of somatic sequence variants obtained by deep sequencing of antibody variable regions in immune repertories from immunized mice, even with a relatively sparse sampling of sequence variants from large sequence datasets. Affinity improvements can be achieved for mAbs with a wide range of affinities. The optimized antibody variants derived from immune repertoire mining have no detectable in vitro off-target binding and have in vivo clearance comparable to the parental mAbs, essential properties in therapeutic antibody leads. As generation of antibody variants in vitro is replaced by mining of variants generated in vivo, the procedure can be applied to rapidly identify affinity-optimized mAb variants.
- 22 March 2019
- Published by Taylor & Francis in mAbs
- Vol. 11 (4) , 735-746
Immune repertoire mining for rapid affinity optimization of mouse monoclonal antibodies
Traditional hybridoma and B cell cloning antibody discovery platforms have inherent limits in immune repertoire sampling depth. One consequence is that monoclonal antibody (mAb) leads often lack the necessary affinity for therapeutic applications, thus requiring labor-intensive and time-consuming affinity in vitro engineering optimization steps. Here, we show that high-affinity variants of mouse-derived mAbs can be rapidly obtained by testing of somatic sequence variants obtained by deep sequencing of antibody variable regions in immune repertories from immunized mice, even with a relatively sparse sampling of sequence variants from large sequence datasets. Affinity improvements can be achieved for mAbs with a wide range of affinities. The optimized antibody variants derived from immune repertoire mining have no detectable in vitro off-target binding and have in vivo clearance comparable to the parental mAbs, essential properties in therapeutic antibody leads. As generation of antibody variants in vitro is replaced by mining of variants generated in vivo, the procedure can be applied to rapidly identify affinity-optimized mAb variants.
- 27 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (22)
Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytes
Loss of function of the nuclear deubiquitinating enzyme BRCA1-associated protein-1 (BAP1) is associated with a wide spectrum of cancers. We report that tamoxifen-induced BAP1 deletion in adult mice resulted in severe thymic atrophy. BAP1 was critical for T cell development at several stages. In the thymus, BAP1 was required for progression through the pre–T cell receptor checkpoint. Peripheral T cells lacking BAP1 demonstrated a defect in homeostatic and antigen-driven expansion. Deletion of BAP1 resulted in suppression of E2F target genes and defects in cell cycle progression, which was dependent on the catalytic activity of BAP1, but did not require its interaction with host cell factor-1 (HCF-1). Loss of BAP1 led to increased monoubiquitination of histone H2A at Lys119 (H2AK119ub) throughout the T cell lineage, in particular in immature thymocytes, but did not alter trimethylation of histone H3 at Lys27 (H3K27me3). Deletion of BAP1 also abrogated B cell development in the bone marrow. Our findings uncover a nonredundant function for BAP1 in maintaining the lymphoid lineage.
- 27 April 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (22)
Tumor suppressor BAP1 is essential for thymic development and proliferative responses of T lymphocytes
Loss of function of the nuclear deubiquitinating enzyme BRCA1-associated protein-1 (BAP1) is associated with a wide spectrum of cancers. We report that tamoxifen-induced BAP1 deletion in adult mice resulted in severe thymic atrophy. BAP1 was critical for T cell development at several stages. In the thymus, BAP1 was required for progression through the pre–T cell receptor checkpoint. Peripheral T cells lacking BAP1 demonstrated a defect in homeostatic and antigen-driven expansion. Deletion of BAP1 resulted in suppression of E2F target genes and defects in cell cycle progression, which was dependent on the catalytic activity of BAP1, but did not require its interaction with host cell factor-1 (HCF-1). Loss of BAP1 led to increased monoubiquitination of histone H2A at Lys119 (H2AK119ub) throughout the T cell lineage, in particular in immature thymocytes, but did not alter trimethylation of histone H3 at Lys27 (H3K27me3). Deletion of BAP1 also abrogated B cell development in the bone marrow. Our findings uncover a nonredundant function for BAP1 in maintaining the lymphoid lineage.
- 6 December 2010
- Published by H1 Connect
- Vol. 2 (60)
Faculty Opinions recommendation of IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient.
The increasing prevalence of inflammatory bowel disease (IBD) has been postulated to result from a lack of exposure to gastrointestinal helminths in most of the western countries. Recently, there has been much interest in exploring the use of helminth products/infection as a therapeutic tool for allergic and autoimmune inflammatory disorders. This paper is a unique, fascinating and detailed study of a single ulcerative colitis (UC)...
- 6 December 2010
- Published by H1 Connect
- Vol. 2 (60)
Faculty Opinions recommendation of IL-22+ CD4+ T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis patient.
The increasing prevalence of inflammatory bowel disease (IBD) has been postulated to result from a lack of exposure to gastrointestinal helminths in most of the western countries. Recently, there has been much interest in exploring the use of helminth products/infection as a therapeutic tool for allergic and autoimmune inflammatory disorders. This paper is a unique, fascinating and detailed study of a single ulcerative colitis (UC)...